Persistent circulating SARS-CoV-2 spike is associated with post-acute COVID-19 sequelae

Zoe Swank\textsuperscript{1,2,3}, Yasmeen Senussi\textsuperscript{1,2,3}, Zachary Manickas-Hill\textsuperscript{4}, Xu G. Yu\textsuperscript{1,4,5}, Jonathan Z. Li\textsuperscript{1,5}, Galit Alter\textsuperscript{4,6}, David R. Walt\textsuperscript{1,2,3}

1. Harvard Medical School, Boston, MA, USA
2. Department of Pathology, Brigham and Women’s Hospital, Boston, MA, USA
3. Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA, USA
4. Ragon Institute of MGH, MIT and Harvard, Cambridge, MA, USA
5. Division of Infectious Diseases, Brigham and Women’s Hospital, Boston, MA, USA
6. Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA

Correspondence: David R. Walt, Department of Pathology, Brigham and Women’s Hospital, Wyss Institute for Biologically Inspired Engineering, Harvard University, Harvard Medical School, Boston, MA, 02115, USA (dwalt@bwh.harvard.edu)

Running title: SARS-CoV-2 spike linked with long COVID
Abstract
The diagnosis of post-acute sequelae of COVID-19 (PASC) poses an ongoing medical challenge. To identify biomarkers associated with PASC we analyzed plasma samples collected from PASC and COVID-19 patients to quantify viral antigens and inflammatory markers. We detect SARS-CoV-2 spike predominantly in PASC patients up to 12 months post-diagnosis.

Keywords
COVID-19, post-acute sequelae of COVID-19 (PASC), long COVID, SARS-CoV-2 antigens, spike
Introduction

While symptoms resulting from infection with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) typically resolve within a few weeks, some individuals experience persistent symptoms following the acute phase of coronavirus disease (COVID-19). The associated syndrome, termed post-acute sequelae of COVID-19 (PASC) or long COVID, encompasses a range of symptoms, affecting multiple organs.\(^1\)

Estimates vary as to the prevalence of PASC, but the World Health Organization (WHO) reports around one quarter of individuals with COVID-19 continue to experience symptoms 4-5 weeks after diagnosis and approximately one in 10 has continuing symptoms after 12 weeks.\(^2\)

Although recent studies provide some clues, the underlying causes of PASC remain elusive.\(^3\) Heterogeneous patient recruitment and inconsistencies in defining PASC patients make it difficult to compare studies and validate current hypotheses. Disentangling the complex biology of PASC will rely on the identification of biomarkers that enable classification of patient phenotypes. Here, we measure SARS-CoV-2 antigen and cytokine levels in plasma samples collected from individuals infected with SARS-CoV-2, some of whom developed PASC.

Materials and Methods

A retrospective pilot study was performed using plasma samples collected from 63 adults who developed acute COVID-19 or PASC. A full description of the patient cohort and sample collection is provided in the Supplementary Materials. SARS-CoV-2
antigens and a panel of 10 cytokines were measured in the collected samples, as described in the Supplementary Materials.

**Results**

We analyzed plasma samples from a cohort of 63 individuals previously infected with SARS-CoV-2, 37 of whom were diagnosed with PASC. For most of the PASC patients (n = 31), blood samples were collected two or more times up to 12 months after their first positive result with a nasopharyngeal swab RT-PCR test. Blood was also collected from individuals who suffered from COVID-19, but were not diagnosed with PASC (hereafter referred to as ‘COVID-19’ patients), up to five months post-diagnosis. The majority of PASC patients were female (n = 30), reflecting the increased frequency with which women are affected by persistent symptoms following SARS-CoV-2 infection. A complete overview of patient characteristics is provided in Table S1 and their reported symptoms are shown in Figure S1.

Using previously developed and optimized ultra-sensitive single molecule array (Simoa) assays (Figure S2), we measured the concentration of SARS-CoV-2 antigens, including the S1 subunit of spike, full length spike, and nucleocapsid (N), in the collected plasma samples (Figure 1). We detected either S1, spike or N in approximately 65% of the patients diagnosed with PASC at any given time point, several months after SARS-CoV-2 infection. Of the three antigens, we detected spike most often in 60% of the PASC patients, whereas we did not detect spike in the COVID-19 patients. S1 was detected to a lesser degree in about one-fifth of the PASC patients and N was detected in a single patient at multiple time points. In line with our previous
work, we detected S1 and N in COVID-19 patients, often those hospitalized with severe disease and within the first week post-diagnosis.

For a subset of PASC and COVID-19 patients, blood samples were collected at multiple times, allowing us to analyze temporal antigen profiles. Of the PASC patients for which we had longitudinal samples, we detected antigen more than once in 12 patients (Figure 2). In only a few cases, the presence of S1 or spike may be correlated with vaccination, however according to our previous findings, S1 is only detected soon after the first dose and spike is rarely detected. Most significantly, we observe sustained spike levels over the course of several months in many patients. In other cases, we observe fluctuations in antigen detectability, indicating that the time of sampling is important. In contrast, temporal antigen profiles of six COVID-19 patients show high antigen levels soon after diagnosis, quickly dropping below the limit of detection (Figure S3).

As PASC is known to affect multiple organ systems, we grouped reported persistent and acute symptoms according to the associated organ system and related those symptoms to whether S1, spike, or nucleocapsid was detected at any given time post infection (Figure S4, S5). We detected antigen in over 70% of patients who reported ongoing cardiovascular, systemic, head-eye-ear-nose-throat (HEENT), and musculoskeletal symptoms. On the other hand, we were more likely to detect antigen in patients who reported acute gastrointestinal and neuropsychiatric symptoms. Furthermore, the greater number of organ systems involved, the higher the probability a given patient was antigen positive.
We also measured the plasma concentrations of a panel of cytokines, including IFN-γ, IL-1β, IL-4, IL-5, IL-6, IL-8, IL-10, IL-12p70, IL-22, and TNF-α, but there were no apparent differences and levels mostly remained within normal ranges (Figure S6, S7).

Discussion

We measured the concentration of SARS-CoV-2 antigens and cytokines in plasma samples collected from PASC and COVID-19 patients. Most notably, we detected circulating SARS-CoV-2 spike in the majority of PASC patients. Although our sample size is small, the detection of spike at multiple time points 2-12 months after infection is an important finding. Temporal fluctuations in antigen levels for a subset of individuals indicates the importance of longitudinal sampling. Furthermore, the minority of our PASC cohort was hospitalized (n=2), suggesting that our findings relate to SARS-CoV-2 infection rather than effects due to severe illness and hospitalization. However, our COVID-19 cohort was more often hospitalized and demographically different, making it difficult to make concrete comparisons. In addition, samples were collected mostly from COVID-19 patients within the first month post-diagnosis and not after five months. Future studies with better matched cohorts and sampling times will be necessary to validate these results.

The presence of circulating spike supports the hypothesis that a reservoir of active virus persists in the body. Another preliminary post-mortem tissue study, found SARS-CoV-2 RNA in multiple anatomic sites up to seven months after symptom onset, corroborating viral antigen persistence. Furthermore, we previously detected elevated levels of spike in children who develop multisystem inflammatory syndrome weeks after
SARS-CoV-2 infection, due to leakage from the gut into the blood stream. Additionally, a recent study detected SARS-CoV-2 RNA shed in the feces up to seven months after initial infection. Although the detection of spike in PASC patients months after diagnosis suggests the presence of replicating viral reservoirs, further analyses are needed to confirm this hypothesis.

If viral reservoirs persist in the body of PASC patients, why do we not also detect N in more patients? It is possible that N is preferentially hydrolyzed, whereas spike may be more efficiently transported into the bloodstream, evading degradation. For instance, SARS-CoV-2 spike was shown to be incorporated in extracellular vesicles circulating in patient blood. Alternatively, circulating anti-N antibodies may be more effective at clearing N compared to the anti-spike antibodies produced. However, after determining the neutralization capacity for anti-spike antibodies in many spike positive samples, we found that spike could be detected even if neutralization levels were high (Figure S8). Furthermore, PASC is a heterogeneous syndrome, possibly dependent on the tissue in which the viral reservoir persists. This heterogeneity may influence whether spike or N is detected; future investigations are necessary to resolve these unanswered questions.

Similarly, we detect S1 at a lower frequency compared with full spike. In principle, we should detect S1 as part of spike; however, our results indicate that both S1 epitopes may not be accessible depending on the conformation of circulating spike. We assume that spike will be incorporated in a membrane, either in viral particles, extracellular vesicles, or remnants of dead infected cells. Given that we calibrate our assay with the spike ectodomain, which is missing the transmembrane domain, we cannot confirm that our S1 assay should bind spike in its natural conformation.
Active viral reservoirs could cause PASC symptoms, but circulating spike may also give rise to symptoms. Similar to bacterial superantigens, SARS-CoV-2 spike contains structural motifs that skew the T cell receptor repertoire, possibly accounting for the hyperinflammatory response observed in severe COVID-19 and MIS-C patients.\textsuperscript{11} Although spike does not instigate a cytokine storm in PASC patients, spike alone has been shown to induce dysfunction in pericytes, vascular endothelial cells, and the blood brain barrier.\textsuperscript{12–14} Alternatively, PASC may manifest as cellular exhaustion or the induction of refractory inflammatory response – but with persistent tissue localized dysfunction. Confined inflammation may also explain why changes in circulating cytokines may be subtle when measured in blood. Other work indicates a trend towards elevated IL-6 and TNF-α in PASC patients\textsuperscript{15} or that the combination of inflammatory mediators is more predictive;\textsuperscript{16} therefore, despite our results, monitoring cytokines over time in a larger cohort warrants further investigation.

In conclusion, the presence of circulating spike in PASC patients up to 12 months post-diagnosis suggests that SARS-CoV-2 viral reservoirs may persist in the body. There are likely many overlapping immunological and inflammatory phenomena contributing to PASC and the detection of spike cannot alone confirm the presence of active viral reservoirs. However, if our finding can be validated in a larger cohort, it would provide strong support for the use of spike as a biomarker for PASC, making it easier to identify patients and assess treatment strategies.
Acknowledgments

Funding for this work came from a generous donation from Barbara and Amos Hostetter. We thank the MassCPR PASC consortium, the Ragon Institute/MassCPR Biobank team, and the Mass General Brigham Biobank for financial and sample processing support.

**Funding:** Dr. Alter reports support from NIH, Moderna, Gates Foundation, Pfizer, Sandofi, Janssen, Abbvie, Medicago, Gilead, and GSK. Dr. Walt reports support from Mass Consortium for Pathogen Readiness and Amos and Barbara Hostetter.

**Potential Conflicts of Interest**

David Walt has a financial interest in Quanterix Corporation, a company that develops an ultra-sensitive digital immunoassay platform. He is an inventor of the Simoa technology, a founder of the company and also serves on its Board of Directors. Dr. Walt's interests were reviewed and are managed by Brigham and Women’s Hospital and Partners Healthcare in accordance with their conflict of interest policies. Dr. Walt also holds stock and stock options for Quanterix Corporation. Dr. Alter reports grants or contracts from Biontech, Merck, and BMS; consulting fees from Sanofi and Moderna, Payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from GSK and Astrazeneca; Patents from REFORM – Antibody Engineergin – MGH; CAPRISA CAP276 HIV monoclonal DSMB; is a part of the Sanofi Scientific Advisory Board; and holds stock or stock options for Systems Seromyx and Leyden Labs.
References:


7. Chertow, Daniel, Stein, Sydney, Ramelli, Alison, et al. SARS-CoV-2 infection and persistence throughout the human body and brain. Published online December 20, 2021. doi:10.21203/rs.3.rs-1139035/v1


FIGURE LEGENDS

Figure 1. SARS-CoV-2 antigen levels versus time. The concentration of S1 (A), spike (B), and N (C) measured in the plasma of individuals over time after diagnosis with PASC or COVID-19 following SARS-CoV-2 infection. Multiple data points may correspond to the same individual, where repeat sampling was available. Data points represent mean values ± SD (n = 2). Dashed lines indicate the LOD for each assay.

Figure 2. Temporal profiling of SARS-CoV-2 antigens for individual PASC patients. S1, spike, and N levels versus time for 12 patients diagnosed with PASC. Data points represent mean values ± SD (n = 2). Grey vertical lines correspond to the times when each patient received either the first, second or third dose of a COVID-19 vaccine. If an individual was not vaccinated within one month of the time frame shown, no vaccination information is shown. Dashed horizontal lines indicate the LOD for each assay.
Figure 1
356x95 mm (x DPI)

Figure 2
454x304 mm (x DPI)